Pfizer Inc. $PFE Stock Bought by D.A. Davidson & CO.

D.A. Davidson & CO. boosted its stake in shares of Pfizer Inc. (NYSE:PFE) by 6.4% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 3,296,392 shares of the biopharmaceutical company’s stock after buying an additional 196,916 shares during the quarter. D.A. Davidson & CO.’s holdings in Pfizer were worth $94,013,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in PFE. Russell Investments Group Ltd. raised its position in shares of Pfizer by 15.7% in the 2nd quarter. Russell Investments Group Ltd. now owns 5,482,863 shares of the biopharmaceutical company’s stock worth $132,365,000 after acquiring an additional 745,213 shares in the last quarter. Handelsbanken Fonder AB lifted its stake in shares of Pfizer by 10.4% in the 2nd quarter. Handelsbanken Fonder AB now owns 2,462,431 shares of the biopharmaceutical company’s stock valued at $59,295,000 after purchasing an additional 232,528 shares during the period. Leuthold Group LLC bought a new stake in shares of Pfizer during the 2nd quarter valued at about $4,887,000. Park National Corp OH boosted its position in shares of Pfizer by 332.1% during the 2nd quarter. Park National Corp OH now owns 242,081 shares of the biopharmaceutical company’s stock valued at $5,829,000 after purchasing an additional 186,053 shares in the last quarter. Finally, 111 Capital bought a new stake in shares of Pfizer during the 2nd quarter valued at about $3,706,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Down 1.1%

Shares of Pfizer stock opened at $29.46 on Thursday. The stock has a market capitalization of $167.90 billion, a PE ratio of 38.76, a price-to-earnings-growth ratio of 2.04 and a beta of 0.32. Pfizer Inc. has a 52 week low of $23.62 and a 52 week high of $30.44. The stock has a 50 day moving average price of $28.46 and a two-hundred day moving average price of $26.74. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%. The company had revenue of $15.03 billion for the quarter, compared to analysts’ expectations of $14.40 billion. During the same period last year, the business earned $0.78 EPS. Pfizer’s quarterly revenue was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities analysts anticipate that Pfizer Inc. will post 2.94 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 7th. Shareholders of record on Friday, November 6th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 5.8%. The ex-dividend date of this dividend is Friday, November 6th. Pfizer’s dividend payout ratio (DPR) is 226.32%.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: ELREXFIO delivered a Phase 3 win. Pfizer said the MagnetisMM-32 trial met its primary endpoint, showing a statistically significant and clinically meaningful progression-free-survival benefit in relapsed or refractory multiple myeloma. The result could support broader use of the drug and strengthen Pfizer’s oncology pipeline. Pfizer’s ELREXFIO Outperforms Standard Regimens and Meets Primary Endpoint
• Positive Sentiment: The FDA expanded the approval of TALZENNA plus XTANDI for earlier-line treatment of metastatic prostate cancer in patients with HRR gene mutations. The broader indication may increase the products’ commercial opportunity and diversify revenue beyond COVID products. FDA expands Pfizer’s Talzenna plus Xtandi approval
• Positive Sentiment: Analyst sentiment remained supportive. Scotiabank and Jefferies issued Buy ratings, while previews suggested Pfizer could beat upcoming earnings expectations. Pfizer’s recent results also exceeded consensus estimates for both revenue and adjusted earnings. Pfizer gets a Buy from Scotiabank
• Neutral Sentiment: Investors are focused on the upcoming Q3 report. Strong sales from newer medicines and a relatively attractive valuation could help, but the earnings release will need to demonstrate that Pfizer can offset ongoing COVID-product declines and longer-term patent risks. Pfizer Stock Ahead of Q3 Earnings
• Negative Sentiment: ELREXFIO’s benefit came with safety concerns. Reports highlighted higher infection rates, while median progression-free survival had not yet been reached. These details may temper the market’s reaction to the otherwise positive trial results. Pfizer’s ELREXFIO meets Phase 3 endpoint
• Negative Sentiment: Valuation and business-transition risks remain. Pfizer’s COVID revenue is declining, major products face future patent expirations, and one valuation analysis placed fair value near the current trading range, limiting perceived upside.

Wall Street Analyst Weigh In

A number of research firms have issued reports on PFE. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a report on Saturday, October 10th. Bank of America lowered their price objective on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research note on Friday, July 10th. BMO Capital Markets dropped their target price on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating on the stock in a research report on Monday, July 13th. Cantor Fitzgerald boosted their target price on shares of Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a research report on Thursday, October 8th. Finally, Scotiabank increased their target price on shares of Pfizer from $30.00 to $33.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 6th. Five equities research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $28.72.

About Pfizer

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.